S
Steven J. Skates
Researcher at Harvard University
Publications - 174
Citations - 21392
Steven J. Skates is an academic researcher from Harvard University. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 68, co-authored 167 publications receiving 19001 citations. Previous affiliations of Steven J. Skates include Fred Hutchinson Cancer Research Center & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Proteogenomics connects somatic mutations to signalling in breast cancer
Philipp Mertins,D. R. Mani,Kelly V. Ruggles,Michael A. Gillette,Michael A. Gillette,Karl R. Clauser,Pei Wang,Xianlong Wang,Jana W. Qiao,Song Cao,Francesca Petralia,Emily Kawaler,Filip Mundt,Filip Mundt,Karsten Krug,Zhidong Tu,Jonathan T. Lei,Michael L. Gatza,Matthew D. Wilkerson,Charles M. Perou,Venkata Yellapantula,Kuan-lin Huang,Chenwei Lin,Michael D. McLellan,Ping Yan,Sherri R. Davies,R. Reid Townsend,Steven J. Skates,Jing Wang,Bing Zhang,Christopher R. Kinsinger,Mehdi Mesri,Henry Rodriguez,Li Ding,Amanda G. Paulovich,David Fenyö,Matthew J. Ellis,Steven A. Carr +37 more
TL;DR: It is demonstrated that proteogenomic analysis of breast cancer elucidates functional consequences of somatic mutations, narrows candidate nominations for driver genes within large deletions and amplified regions, and identifies therapeutic targets.
Journal ArticleDOI
Proteogenomic characterization of human colon and rectal cancer
Bing Zhang,Jing Wang,Xiaojing Wang,Jing Zhu,Qi Liu,Zhiao Shi,Matthew C. Chambers,Lisa J. Zimmerman,Kent Shaddox,Sangtae Kim,Sherri R. Davies,Sean Wang,Pei Wang,Christopher R. Kinsinger,Robert Rivers,Henry Rodriguez,R. Reid Townsend,Matthew J. Ellis,Steven A. Carr,Steven A. Carr,David L. Tabb,Robert J. Coffey,Robbert J.C. Slebos,Daniel C. Liebler,Michael A. Gillette,Karl R. Klauser,Eric Kuhn,D. R. Mani,Philipp Mertins,Karen A. Ketchum,Amanda G. Paulovich,Jeffrey R. Whiteaker,Nathan Edwards,Peter B. McGarvey,Subha Madhavan,Daniel W. Chan,Akhilesh Pandey,Ie Ming Shih,Hui Zhang,Zhen Zhang,Heng Zhu,Gordon Whiteley,Steven J. Skates,Forest M. White,Douglas A. Levine,Emily S. Boja,Tara Hiltke,Mehdi Mesri,Kenna M. Shaw,Stephen E. Stein,David Fenyö,Tao Liu,Jason E. McDermott,Samuel H. Payne,Karin D. Rodland,Richard D. Smith,Paul A. Rudnick,Michael Snyder,Yingming Zhao,Xian Chen,David F. Ransohoff,Andrew N. Hoofnagle,Melinda E. Sanders,Yue Wang,Li Ding +64 more
TL;DR: Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.
Journal ArticleDOI
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma
Terri A. Addona,Susan E. Abbatiello,Birgit Schilling,Steven J. Skates,D. R. Mani,David M. Bunk,Clifford H. Spiegelman,Lisa J. Zimmerman,Amy-Joan L. Ham,Hasmik Keshishian,Steven C. Hall,Simon Allen,Ronald K. Blackman,Christoph H. Borchers,Charles Buck,Helene L. Cardasis,Michael P. Cusack,Nathan G. Dodder,Bradford W. Gibson,Jason M. Held,Tara Hiltke,Angela M. Jackson,Eric B. Johansen,Christopher R. Kinsinger,Jing Li,Mehdi Mesri,Thomas A. Neubert,Richard K. Niles,Trenton C. Pulsipher,David F. Ransohoff,Henry Rodriguez,Paul A. Rudnick,Derek Smith,David L. Tabb,Tony J. Tegeler,Asokan Mulayath Variyath,Lorenzo Vega-Montoto,Asa Wahlander,Sofia Waldemarson,Mu Wang,Jeffrey R. Whiteaker,Lei Zhao,N. Leigh Anderson,Susan J. Fisher,Daniel C. Liebler,Amanda G. Paulovich,Fred E. Regnier,Paul Tempst,Steven A. Carr +48 more
TL;DR: A multilaboratory study to assess reproducibility, recovery, linear dynamic range and limits of detection and quantification of multiplexed, MRM-based assays, conducted by NCI-CPTAC demonstrates that these assays can be highly reproducible within and across laboratories and instrument platforms.
Journal ArticleDOI
An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
TL;DR: Among patients with atrial fibrillation, anticoagulant prophylaxis is effective at INRs of 2.0 or greater, and tight control of anticoAGulant therapy to maintain the INR between2.0 and 3.0 is a better strategy than targeting lower, less effective levels of antICOagulation.
Journal ArticleDOI
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Ian Jacobs,Ian Jacobs,Ian Jacobs,Usha Menon,Andy Ryan,Aleksandra Gentry-Maharaj,Matthew Burnell,Jatinderpal Kalsi,Nazar Najib Amso,Sophia Apostolidou,Elizabeth Benjamin,Derek Cruickshank,Danielle N. Crump,Susan K Davies,Anne Dawnay,Stephen Dobbs,Gwendolen Fletcher,Jeremy Ford,Jeremy Ford,Keith M. Godfrey,Richard Gunu,Mariam Habib,Mariam Habib,Rachel Hallett,Rachel Hallett,Jonathan Herod,Howard Jenkins,Chloe Karpinskyj,Simon Leeson,Sara Lewis,William R. Liston,Alberto Lopes,Tim Mould,Tim Mould,John Murdoch,David H. Oram,Dustin J. Rabideau,K. Reynolds,Ian Scott,Mourad W. Seif,Mourad W. Seif,A. Sharma,A. Sharma,Naveena Singh,Julie Taylor,Fiona Warburton,Fiona Warburton,Martin Widschwendter,Karin Williamson,Robert Woolas,Robert Woolas,Lesley Fallowfield,Alistair McGuire,Stuart Campbell,Mahesh K. B. Parmar,Steven J. Skates +55 more
TL;DR: Although the mortality reduction was not significant in the primary analysis, it was noted a significant mortality reduction with MMS when prevalent cases were excluded, and encouraging evidence of a mortality reduction in years 7–14 was noted.